8-K: PepGen Reports Q2 2025 Results, DM1 Trial Progress

PepGen Inc. announced its second quarter 2025 financial results and significant progress in its PGN-EDODM1 clinical program for Myotonic Dystrophy Type 1, including completing dosing in the FREEDOM-DM1 trial's 15 mg/kg cohort and advancing to the FREEDOM2 multiple ascending dose study.

Summary

• Reported financial results and corporate highlights for the quarter ended June 30, 2025.
• Completed patient dosing in the 15 mg/kg cohort of the FREEDOM Phase 1 Single Ascending Dose (SAD) trial for PGN-EDODM1.
• Topline data from the 15 mg/kg cohort of the FREEDOM trial is on track to be reported in early Q4 2025.
• Decision made to conclude dose escalation in the FREEDOM trial with the 15 mg/kg cohort, based on robust splicing correction observed at 5 and 10 mg/kg doses and the totality of blinded safety data.
• Resources will now be redirected to the FREEDOM2 Phase 2 Multiple Ascending Dose (MAD) trial, with clinical sites beginning to transition.
• Results from the 5 mg/kg cohort of the FREEDOM2 trial are expected in the first quarter of 2026.
• Cash, Cash Equivalents and Marketable Securities were $74.7 million as of June 30, 2025.
• Existing cash, cash equivalents, and marketable securities are believed to be sufficient to fund operations into the second quarter of 2026.
• Research and Development Expenses were $18.4 million for the three months ended June 30, 2025, a decrease from $25.1 million for the same period in 2024.
• General and Administrative Expenses were $5.5 million for the three months ended June 30, 2025, a slight increase from $5.4 million for the same period in 2024.
• Net Loss was $23.1 million, or $(0.70) basic and diluted net loss per share, for the three months ended June 30, 2025, compared to $28.3 million, or $(0.87) per share, for the same period in 2024.
• Approximately 32.8 million shares were outstanding on June 30, 2025.

Sentiment

Score: 8

Explanation: The filing presents strong positive clinical progress with the lead candidate PGN-EDODM1, including completion of dosing in a key trial cohort and strategic advancement to a multiple ascending dose study based on promising early data. Financial results show a reduced net loss and R&D expenses, indicating improved cost management. The appointment of a new CTO also adds to positive sentiment. While the company continues to incur losses, the clinical milestones and strategic resource allocation are significant positives for a clinical-stage biotech.

Positives

• Completed patient dosing in the 15 mg/kg cohort of the FREEDOM-DM1 trial, remaining on track for topline data in early Q4 2025.
• Strategic decision to conclude the FREEDOM trial with the 15 mg/kg cohort, based on robust splicing correction at lower doses (5 and 10 mg/kg) and emerging safety, allowing for efficient resource redirection to the FREEDOM2 trial.
• PGN-EDODM1 demonstrates 'class-leading mean mis-splicing correction' following a single 10 mg/kg dose, indicating potential as a best-in-class treatment for DM1.
• Net loss decreased to $23.1 million in Q2 2025 from $28.3 million in Q2 2024, reflecting improved financial performance.
• Research and Development Expenses decreased significantly to $18.4 million in Q2 2025 from $25.1 million in Q2 2024, suggesting more efficient R&D spending or phase transitions.
• Appointed Kasra Kasraian, PhD, as Chief Technology Officer in May 2025, bringing over 25 years of relevant experience in product and process development.
• PGN-EDODM1 has received Orphan Drug and Fast Track Designations from the U.S. Food and Drug Administration for the treatment of DM1.

Negatives

• Continued to incur a net loss of $23.1 million for the quarter.
• Cash, cash equivalents, and marketable securities decreased from $120.191 million at December 31, 2024, to $74.653 million at June 30, 2025, indicating ongoing cash burn.
• General and Administrative Expenses slightly increased to $5.5 million in Q2 2025 from $5.4 million in Q2 2024.

Risks

• Delays or failure to successfully initiate or complete ongoing and planned development activities for current or future product candidates, including PGN-EDODM1.
• Inability to enroll patients in clinical trials, including FREEDOM and FREEDOM2.
• Interpretation of clinical and preclinical study results may be incorrect, or anticipated levels of therapeutic activity may not be observed in clinical testing.
• Current and future product candidates, including PGN-EDODM1, may not be safe and effective or otherwise demonstrate safety and efficacy in clinical trials.
• Adverse outcomes from regulatory interactions, including delays in regulatory review, clearance to proceed, or approval by regulatory authorities.
• Changes in regulatory framework that are out of the company's control.
• Unexpected increases in expenses associated with development activities or other events that adversely impact financial resources and cash runway.
• Dependence on third parties for some or all aspects of product manufacturing, research, and preclinical and clinical testing.

Future Outlook

PepGen expects to report topline data from the 15 mg/kg cohort of the FREEDOM trial in early Q4 2025 and results from the 5 mg/kg cohort of the FREEDOM2 trial in Q1 2026. The company anticipates its existing cash, cash equivalents, and marketable securities will be sufficient to fund operations into the second quarter of 2026.

Management Comments

• "This quarter, we made further progress in the development of our promising myotonic dystrophy type 1 program, PGN-EDODM1."
• "With class-leading mean mis-splicing correction following a single 10 mg/kg dose, we believe PGN-EDODM1 has the potential to become a best-in-class treatment for patients with DM1."
• "Having recently completed patient dosing in the 15 mg/kg arm of our single ascending dose FREEDOM trial (PGN-EDODM1-101), we look forward to sharing topline data from this cohort in early Q4 2025."
• "Furthermore, the efficacy and emerging safety profile of PGN-EDODM1 supports our decision to conclude the FREEDOM trial with the 15 mg/kg single dose cohort, with the additional benefit of being able to now transition clinical sites to the FREEDOM2 trial (PGN-EDODM1-102), our multiple ascending dose trial."
• "Our FREEDOM2 trial is designed to demonstrate that sustained mis-splicing correction with multiple doses of PGN-EDODM1 can produce meaningful functional improvements in patients with DM1."
• "Were looking forward to reporting results from the initial dose cohort of FREEDOM2 in the first quarter of 2026."

Industry Context

PepGen operates in the clinical-stage biotechnology sector, specifically focusing on oligonucleotide therapies for severe neuromuscular and neurological diseases. Its lead candidate, PGN-EDODM1, targets Myotonic Dystrophy Type 1 (DM1), a rare genetic disorder affecting an estimated 40,000 people in the U.S. and over 74,000 in Europe. The company's proprietary Enhanced Delivery Oligonucleotide (EDO) platform aims to improve drug uptake and activity, positioning it within the competitive landscape of gene and oligonucleotide therapies seeking to address the root causes of genetic diseases. The focus on DM1, a disease with significant unmet medical need and Orphan Drug/Fast Track designations, highlights its strategy to target high-impact, underserved patient populations.

Comparison to Industry Standards

• The filing highlights PGN-EDODM1's 'class-leading mean mis-splicing correction' at a 10 mg/kg dose, but does not provide specific comparative data against other investigational or approved DM1 treatments for a detailed assessment against industry standards.

Management Changes

Stakeholder Impact

• Shareholders: Positive impact from clinical progress, potential for a best-in-class DM1 treatment, and reduced net loss, which could lead to increased shareholder value if trials continue successfully.
• Patients (DM1): Potential for a new, effective treatment option (PGN-EDODM1) that could offer meaningful functional improvements and address the root cause of their progressively disabling disease.
• Employees: Continued employment and potential growth opportunities within a company making significant clinical advancements.
• Creditors/Suppliers: Continued business relationships as the company progresses its clinical programs, supported by its cash runway into Q2 2026.

Next Steps

• Report topline data from the 15 mg/kg cohort of the FREEDOM trial in early Q4 2025.
• Transition clinical sites from the FREEDOM trial to the FREEDOM2 trial.
• Report results from the 5 mg/kg cohort of the FREEDOM2 trial in Q1 2026.

Key Dates

Recommendation

While the clinical progress for PGN-EDODM1 is promising, with positive early data and strategic advancement to a Phase 2 trial, the company remains in a clinical-stage with significant cash burn and no revenue. The cash runway extends only into Q2 2026, suggesting a potential need for future capital raises. The stock is highly speculative, dependent on successful clinical trial outcomes. Given the positive clinical momentum but also the inherent risks and limited cash runway of a clinical-stage biotech, a 'hold' recommendation is appropriate for investors who already have exposure, awaiting further definitive clinical data from the FREEDOM2 trial and clarity on long-term funding.

Keywords

Biotechnology, Clinical-stage, Oligonucleotide therapies, Neuromuscular diseases, Neurological diseases, Myotonic Dystrophy Type 1, DM1, PGN-EDODM1, EDO platform, Clinical trials, Phase 1, Phase 2, FREEDOM trial, FREEDOM2 trial, Drug development, Orphan Drug, Fast Track Designation, Financial results, Q2 2025